γ-secretase modulators: Hopes and setbacks for the future of Alzheimer's treatment

Expert Review of Neurotherapeutics

Volumn 8, Issue 11, 2008, Pages 1611-1613

  Evin, Genevieve ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTERIOR PHARYNX 1; ASPARTIC PROTEINASE INHIBITOR; BETA SECRETASE; FENOFIBRATE; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GLYCOPROTEIN; IBUPROFEN; INDOMETACIN; MEMBRANE PROTEIN; NAPROXEN; NICASTRIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRESENILIN 1; PRESENILIN 2; PRESENILIN ENHANCER 2; SULINDAC SULFIDE; TARENFLURBIL; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BLOOD BRAIN BARRIER; CLINICAL TRIAL; EDITORIAL; ENCEPHALITIS; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; GENE EXPRESSION; HUMAN; LEARNING DISORDER; NEUROPATHOLOGY; NONHUMAN; OLIGOMERIZATION; PROTEIN AGGREGATION; PROTEIN DEGRADATION; RECOMBINANT GENE; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BRAIN; ENZYME INHIBITORS; HUMANS;

EID: 55849121517     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.11.1611     Document Type: Editorial

References (24)

1. Masters C, Beyreuther K. Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain 129(Pt 11), 2823-2839 (2006).
2. Evin G, Sernee MF, Masters CL. Inhibition of γ-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 20, 351-372 (2006).
3. Iwatsubo T. The γ-secretase complex: machinery for intramembrane proteolysis. Curr. Opin. Neurobiol. 14(3), 379-383 (2004).
4. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature 398(6727), 513-517 (1999). • Demonstrates that the multipass membrane protein presenilin is a proteolytic enzyme.
5. Lazarov V, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, Li H. Electron microscopic structure of purified, active γ-secretase reveals an aqueous intramembrane chamber and two pores. Proc. Natl Acad. Sci. USA 103(18), 6889-6894 (2006).
6. Sato C, Morohashi Y, Tomita T, Iwatsubo T. Structure of the catalytic pore of γ-secretase probed by the accessibility of substituted cysteines. J. Neurosci. 26, 12081-12088 (2006).
7. De Strooper B, Annaert W, Cupers P et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518-522 (1999). • First report that γ-secretase cleaves other substrates than amyloid precursor protein (APP) and is involved in signaling.
8. Lim G, Yang F, Chu, T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714 (2000). • First study showing that a NSAID inhibits amyloid β (Aβ) plaque formation.
9. 40.
10. Beher D, Clarke EE, Wrigley JD et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. 279, 43419-43426 (2004).
11. 42 and change presenilin 1 conformation. Nat. Med. 10, 1065-1066 (2004).
12. 42 in vivo. J. Clin. Invest. 112, 440-449 (2003). • Shows for the first time that some NSAID directly interfere with γ-secretase cleavage of APP.
13. Kukar T, Prescott S, Eriksen JL et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 8, 54 (2007).
14. 42 production. Nat. Med. 11, 545-550 (2005).
15. Kukar TL, Ladd TB, Bann MA et al. Substrate-targeting γ-secretase modulators. Nature 453, 925-929 (2008).
16. Ren Z, Schenk D, Basi GS, Shapiro IP. Amyloid-protein precursor juxtamembrane domain regulates specificity of γ-secretase-dependent cleavages. J. Biol. Chem. 282, 35350-35360 (2007).
17. Thinakaran G, Koo E. γ trafficking, processing and function. J. Biol. Chem. (2008) (Epub ahead of print).
18. Wilcock G, Black S, Hendrix S et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised Phase II trial. Lancet Neurol. 7, 483-493 (2008).
19. Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. Direct and potent regulation of γ-secretase by its lipid microenvironment. J. Biol. Chem. 283, 22529-22540 (2008).
20. Gamerdinger M, Clement A, Behl C. Effects of sulindac sulfide on the membrane architecture and the activity of γ-secretase. Neuropharmacology 254, 998-1005 (2008).
21. Chen F, Hasegawa H, Schmitt-Ulms G et al. TMP21 is a presenilin complex component that modulates γ-secretase but not ε-secretase activity. Nature 440, 1208-1212 (2006).
22. Serneels L, Van Biervliet J, Craessaerts K et al. Aph1b γ-secretase generates long Aβ peptides and genetic ablation improves Alzheimer's disease phenotypes without affecting notch signaling in the mouse. Alzheimer's and dementia 4(Suppl. 2), T136 (2008) (Abstract 9O2-03-04).
23. Fagan T. Merck withdraws Vioxx. 30 September 2004 www.alzforum.org/new/ detailprint.asp?id=1083 (Accessed 20 August 2008)
24. Alzheimer Association. Four Alzheimer's clinical trials address a variety of treatment targets - amyloid, tau, synapse formation. July 29 2008 www.alz.org/icad/_release_icad_072908_130pm_trials.asp (Accessed 20 August 2008)